Nerve stimulation for treatment of diseases and disorders
View Patent ↗Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.
1. A method for treating a subject having a disease or disorder comprising electrically stimulating at least one vagus nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder,
wherein the disease or disorder is selected from the group consisting of elevated blood glucose levels, decreased blood glucose levels and inflammation, and
wherein blood glucose levels are decreased in the subject by electrically stimulating the vagus nerve with a corrective stimulus pattern derived from a hypoglycemia-specific, insulin-specific or cortisol-specific neurogram recorded from a vagus nerve in an amount and manner effective to decrease blood glucose levels in a subject, or
wherein blood glucose levels are increased in the subject by electrically stimulating the vagus nerve with a corrective stimulus pattern derived from a hyperglycemia-specific or glucose-specific neurogram recorded from a vagus nerve in an amount and manner effective to increase blood glucose levels in a subject, or
wherein inflammation is treated in the subject by electrically stimulating the vagus nerve of the subject with a corrective stimulus pattern derived from an anti-inflammatory cytokine-specific or cortisol-specific or dexamethasone-specific neurogram recorded from a vagus nerve in an amount and manner effective to reduce a sign or symptom of inflammation in a subject.
2. The method of claim 1 , wherein the cervical vagus nerve is electrically stimulated with a corrective stimulus pattern derived from a hypoglycemia-specific neurogram recorded from a vagus nerve.
3. The method of claim 1 , wherein the cervical vagus nerve is electrically stimulated with a corrective stimulus pattern derived from an insulin-specific neurogram recorded from a vagus nerve.
4. The method of claim 3 , wherein the decrease in blood glucose levels is mediated by vagal afferent signaling.
5. The method of claim 1 , wherein the hypoglycemia-specific neurogram is recorded from a vagus nerve of a subject following administration of insulin or cortisol to the subject.
6. The method of claim 1 , wherein the subject requiring treatment for elevated blood glucose levels has one or more of diabetes mellitus type 1, diabetes mellitus type 2, metabolic syndrome, glucose intolerance, insulin resistance or hyperglycemia.
7. The method of claim 1 , wherein the hyperglycemia-specific neurogram is recorded from a vagus nerve of a subject following administration of glucose to the subject.
8. The method of claim 1 , wherein the subject requiring treatment for decreased blood glucose levels has one or more of hypoglycemia, kidney failure, liver disease or hypothyroidism.
9. The method of claim 1 , wherein the anti-inflammatory cytokine is interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-13 (IL-13) or interleukin-35 (IL-35).
10. The method of claim 1 , wherein electrical stimulation of the cervical vagus nerve with the corrective stimulus pattern derived from an anti-inflammatory cytokine-specific or cortisol-specific or dexamethasone-specific neurogram increases serum levels of one or more anti-inflammatory cytokines.
11. The method of claim 10 , wherein the anti-inflammatory cytokine is one or more of interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-13 (IL-13) or interleukin-35 (IL-35).
12. The method of claim 1 , wherein electrical stimulation of the cervical vagus nerve with the corrective stimulus pattern derived from an anti-inflammatory cytokine-specific or cortisol-specific or dexamethasone-specific neurogram decreases serum levels of one or more inflammatory cytokines.
13. The method of claim 12 , wherein the inflammatory cytokine is one or more of interleukin-1β (IL-1β) or tumor necrosis factor (TNF).
14. The method of claim 1 , wherein the subject with inflammation has one or more of rheumatoid arthritis, colitis, inflammatory bowel disease, Crohn's Disease, or an infection.
15. The method of claim 1 , wherein the corrective stimulus pattern is applied to the cervical vagus nerve and wherein physiologic effects of the corrective stimulus pattern are mediated by vagal nerve afferents.
16. The method of claim 1 , wherein the neurogram is obtained from an animal model or a human patient.
17. The method of claim 1 , wherein nerve recording and/or nerve stimulation are carried out using implanted electrodes.